| Ankylosing spondylitis
Cosentyx vs Vimovo
Side-by-side clinical, coverage, and cost comparison for ankylosing spondylitis.Deep comparison between: Cosentyx vs Vimovo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVimovo has a higher rate of injection site reactions vs Cosentyx based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vimovo but not Cosentyx, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cosentyx
Vimovo
At A Glance
SC injection
Every 4 weeks
IL-17A antagonist
Oral
Twice daily
NSAID + Proton Pump Inhibitor
Indications
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Non-Radiographic Axial Spondyloarthritis
- Enthesitis-Related Arthritis
- Hidradenitis Suppurativa
- Degenerative polyarthritis
- Rheumatoid Arthritis
- Ankylosing spondylitis
- Juvenile arthritis
Dosing
Psoriasis vulgaris 300 mg SC at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; 150 mg may be acceptable for some adults; pediatric patients 6 years and older receive weight-based dosing on the same schedule.
Arthritis, Psoriatic 150 mg SC with or without a loading dose at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; may increase to 300 mg SC every 4 weeks if active disease persists; IV option: 6 mg/kg loading at Week 0, then 1.75 mg/kg every 4 weeks infused over 30 minutes.
Ankylosing spondylitis 150 mg SC with or without a loading dose at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; may increase to 300 mg SC every 4 weeks if active disease persists; IV option: 6 mg/kg loading at Week 0, then 1.75 mg/kg every 4 weeks infused over 30 minutes.
Non-Radiographic Axial Spondyloarthritis 150 mg SC with or without a loading dose at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; IV option: 6 mg/kg loading at Week 0, then 1.75 mg/kg every 4 weeks infused over 30 minutes.
Enthesitis-Related Arthritis Weight-based SC dosing for pediatric patients 4 years and older at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; 150 mg for patients >= 50 kg.
Hidradenitis Suppurativa 300 mg SC at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; may increase to every 2 weeks in adults with inadequate response; pediatric patients 12 years and older receive weight-based dosing every 4 weeks.
Degenerative polyarthritis, Rheumatoid Arthritis, Ankylosing spondylitis Adults: one tablet (375 mg or 500 mg naproxen/20 mg esomeprazole) twice daily, taken orally at least 30 minutes before meals; use lowest effective naproxen dose for shortest duration.
Juvenile arthritis Adolescents >=12 years and >50 kg: one tablet (375 mg or 500 mg naproxen/20 mg esomeprazole) twice daily; 38 kg to <50 kg: one tablet (375 mg naproxen/20 mg esomeprazole) twice daily, taken at least 30 minutes before meals.
Contraindications
- Previous serious hypersensitivity reaction to secukinumab or any excipient in COSENTYX
- Known hypersensitivity to naproxen, esomeprazole magnesium, substituted benzimidazoles, or any components of the drug product, including omeprazole
- History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
- Coronary artery bypass graft (CABG) surgery
- Concomitant use of rilpivirine-containing products
Adverse Reactions
Most common (>=1%) nasopharyngitis, diarrhea, upper respiratory tract infection, rhinitis, oral herpes, pharyngitis, urticaria, rhinorrhea
Serious infections (including serious infections and sepsis), inflammatory bowel disease (Crohn's disease and ulcerative colitis), neutropenia, anaphylaxis, angioedema
Postmarketing anaphylaxis, angioedema, systemic vasculitis, eczematous eruptions, cutaneous vasculitis, pyoderma gangrenosum, opportunistic infections including esophageal candidiasis, cytomegalovirus gastroenteritis/colitis, Pneumocystis jiroveci pneumonia, hepatitis B virus reactivation, histoplasmosis, toxoplasmosis
Most common (>2%) Gastritis, diarrhea, upper respiratory tract infection, flatulence, headache, urinary tract infection, dysgeusia
Serious Cardiovascular thrombotic events, GI bleeding/ulceration/perforation, hepatotoxicity, hypertension, heart failure and edema, renal toxicity and hyperkalemia, anaphylactic reactions, serious skin reactions, DRESS, fetal toxicity, hematologic toxicity
Postmarketing Gait disturbance, abdominal distension, hematochezia, joint swelling, muscle spasms, renal tubular necrosis, angioedema, aplastic anemia, hepatitis, Stevens-Johnson Syndrome, toxic epidermal necrolysis, hypomagnesemia, cutaneous lupus erythematosus
Pharmacology
Secukinumab is a human IgG1 monoclonal antibody that selectively binds to the IL-17A cytokine and inhibits its interaction with the IL-17 receptor, suppressing the release of proinflammatory cytokines and chemokines involved in inflammatory and immune responses.
VIMOVO is a fixed-dose combination of naproxen, an NSAID that inhibits cyclooxygenase (COX-1 and COX-2) to reduce prostaglandin synthesis with analgesic, anti-inflammatory, and antipyretic effects, and esomeprazole magnesium, a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase in the gastric parietal cell to reduce naproxen-associated gastric ulcer risk.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cosentyx
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Vimovo
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (1/12)
UnitedHealthcare
Cosentyx
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (1/8) · Qty limit (4/8)
Vimovo
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Cosentyx
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Vimovo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Ankylosing Spondylitis: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
No savings programs available for Vimovo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CosentyxView full Cosentyx profile
VimovoView full Vimovo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.